Our observation of poorer RFS in some breast cancer subtypes with high ORAI3 and low ORAI1 levels, is reflective of the association between the ORAI1 activators STIM1/STIM2 in basal breast cancers, where high STIM1/low STIM2 was associated with poorer survival [11]. Here, ORAI3 is linked to breast carcinoma.